NuVasive’s acquisition of Ellipse represents its entry into the early onset and idiopathic scoliosis treatment arena, and could lead to partnerships in the treatment of trauma and knee osteoarthritis.
Ellipse’s magnetically-adjustable implant systems are based on its MAGnetic External Control (MAGEC®) technology, and include MAGEC−EOS spinal bracing and distraction for treatment of early onset scoliosis and the PRECICE® limb lengthening system.
The acquisition is expected to close in mid-1Q16.
Having agreed to be acquired by NuVasive, Ellipse Technologies has withdrawn plans for a US $75MM initial public offering filed in 4Q15.
NuVasive's acquisition of Ellipse represents its entry into the early onset and idiopathic scoliosis treatment arena, and could lead to partnerships in the treatment of...
Having agreed to be acquired by NuVasive, Ellipse Technologies has withdrawn plans for a US $75MM initial public offering filed in 4Q15.
NuVasive’s acquisition of Ellipse represents its entry into the early onset and idiopathic scoliosis treatment arena, and could lead to partnerships in the treatment of trauma and knee osteoarthritis.
Ellipse’s magnetically-adjustable implant systems are based on its MAGnetic External Control (MAGEC®) technology, and include MAGEC−EOS spinal bracing and distraction for treatment of early onset scoliosis and the PRECICE® limb lengthening system.
The acquisition is expected to close in mid-1Q16.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
